ReShape diabetes neuromodulation device encouraging in preclinical

ReShape Lifesciences (OTCQB:RSLS +11.0%) has announced preclinical research demonstrating its investigational Diabetes Bloc-Stim Neuromodulation (DBSN) device, for the treatment of type 2 diabetes mellitus, was well-tolerated and met the study endpoints.

Histopathology of organ systems effected by the neuromodulation demonstrated healthy tissue.

https://seekingalpha.com/news/3612988-reshape-lifesciencess-diabetes-neuromodulation-device-shows-encouraging-effect-in-preclinical